SomnoMed (ASX:SOM) said its revenue for the quarter ended Dec. 31, 2024, grew 20% year-over-year to AU$28.5 million, according to a Friday Australian bourse filing.
Its revenue in the fiscal second quarter reported a jump in all geographies, with North America and Asia-Pacific achieving double-digit increases.
It updated its guidance for the fiscal year ending June 30, now expecting a revenue of about AU$105 million as well as earnings before interest, taxes, depreciation, and amortization of between AU$7 million to AU$9 million.
The firm's shares rose 10% in recent trading on Friday.